Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUBASKET
2024-519346-75-00Phase 2Authorised
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lu-PNT2002 in Nonhematologic neoplasms, prostate cancer (PCa) and brain neoplasm, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Disease control rate at first evaluation and Acute safety. Planned start Jan 2025; status: authorised.
02
Drugs
Lu-PNT2002
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)brain neoplasm
Beyond the preview
Go deeper on 2024-519346-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519346-75-00.